Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer
Dipenkumar Modi(Wayne State University), Elisabeth I. Heath(The Barbara Ann Karmanos Cancer Institute), H. Gayar(McLaren Health Care), Richard Joyrich(Wayne State University), Clara Hwang(Henry Ford Health System), Ulka N. Vaishampayan(University of Michigan), Seongho Kim(Wayne State University), Hirva Mamdani(Wayne State University)
Cited by 27
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
|New England Journal of Medicine|2013|568
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373